glp 1 agonist parkinson A New Treatment Strategy for Parkinson's Disease through the Gut–Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway Major physiological roles of GLP-1

But insulin dose reduction needs to be done carefully and gradually, with close CGM monitoring, to avoid either hypoglycemia (from too much insulin relative to your new needs) or hyperglycemia (from reducing too aggressively)

Ein anderer Ansatz zur Entwicklung langwirkender GLP-1-RA war die Anbindung leicht modifizierter GLP-1-Molekle an groe Eiweimolekle (Immunglobulin-Fragmente im Falle von Dulaglutid und Efpeglenatid, Albumin im Falle von Albiglutid) (23, 24)

These trials should be thoughtfully designed to encompass diverse patient populations, investigate varying doses of GLP-1 RAs, and incorporate extended follow-up periods

Additionally, 49% of patients on the 30 mg dose achieved HbA1c levels below 7%, compared to only 21% in the placebo group

Fabregat, A

As GLP-1-RAs use increases, clinicians may need extra training to initiate and maintain treatment